Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England’s Innovative Medicines Fund: Opportunities & Risks

Executive Summary

England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.

You may also be interested in...



England Launches Innovative Medicines Fund

The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.

Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing

Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.

Pfizer Ponders Next Move After English HTA Rejects Oxbryta Again Despite Appeal

In spite of successfully appealing against previous negative guidance, Pfizer has again failed to secure a positive recommendation from England’s health technology appraisal institute for Oxbryta for hemolytic anemia caused by sickle cell disease, and has been asked to provide more evidence.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel